Abstract:Purinergic signaling is a crucial determinant in the regulation of pulmonary vascular physiology and presents a promising avenue for addressing lung diseases. This intricate signaling system encompasses two primary receptor classes: P1 and P2 receptors. P1 receptors selectively bind adenosine, while P2 receptors exhibit an affinity for ATP, ADP, UTP, and UDP. Functionally, P1 receptors are associated with vasodilation, while P2 receptors mediate vasoconstriction, particularly in basally relaxed vessels, through modulation of intracellular Ca 2+ levels. The P2X subtype receptors facilitate extracellular Ca 2+ influx, while the P2Y subtype receptors are linked to endoplasmic reticulum Ca 2+ release. Notably, the primary receptor responsible for ATP-induced vasoconstriction is P2X1, with α,β-meATP and UDP being identified as potent vasoconstrictor agonists. Interestingly, ATP has been shown to induce endothelium-dependent vasodilation in pre-constricted vessels, associated with nitric oxide (NO) release. In the context of P1 receptors, adenosine stimulation of pulmonary vessels has been unequivocally demonstrated to induce vasodilation, with a clear dependency on the A 2B receptor, as evidenced in studies involving guinea pigs and rats. Importantly, evidence strongly suggests that this vasodilation occurs independently of endothelium-mediated mechanisms. Furthermore, studies have revealed variations in the expression of purinergic receptors across different vessel sizes, with reports indicating notably higher expression of P2Y 1 , P2Y 2 , and P2Y 4 receptors in small pulmonary arteries. While the existing evidence in this area is still emerging, it underscores the urgent need for a comprehensive examination of the specific characteristics of purinergic signaling in the regulation of pulmonary vascular tone, particularly focusing on the disparities observed across different intrapulmonary vessel sizes. Consequently, this review aims to meticulously explore the current evidence regarding the role of purinergic signaling in pulmonary vascular tone regulation, with a specific emphasis on the variations observed in intrapulmonary vessel sizes. This endeavor is critical, as purinergic signaling holds substantial promise in the modulation of vascular tone and in the proactive prevention and treatment of pulmonary vascular diseases.

Purinergic signalling in the reproductive system in health and disease

Purinergic signalling in endocrine organs

Ectonucleotidases and Purinergic Receptors in Mouse Prostate Gland

Long-term (trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death

Purinergic signalling during development and ageing

Introduction to Purinergic Signaling

From purines to purinergic signalling: molecular functions and human diseases

Cardiac purinergic signalling in health and disease

Purinergic signalling and immune cells

Influence of extracellular ATP on mammalian sperm physiology

Purinergic signalling in spinal pain processing

Editorial - Purinergic signalling: 50 years

Purine and purinergic receptors in health and disease

Purine and purinergic receptors

Purinergic regulation of pulmonary vascular tone

The Purinergic Agonists Atp and Utp Act Predominantly Via P2y Receptors in Human Vascular Endothelial Cells

Purinergic Regulation of Neutrophil Function

Blood cells: an historical account of the roles of purinergic signalling

Adenosine 5′-triphosphate and its relationship with other mediators that activate pelvic nerve afferent neurons in the rat colorectum

Purinergic signalling in liver diseases: Pathological functions and therapeutic opportunities

Role of purinoreceptors in the release of extracellular vesicles and consequences on immune response and cancer progression